ScholarIQanswers from OpenAlex & ORCID
Bruce Strober
ResearcherPublications, citations & collaboration network
Bruce Strober is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Bruce Strober have?
ScholarIQindexed works
Bruce Strober has 477 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Bruce Strober have?
ScholarIQcitation count
Bruce Strober has 19,920 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Bruce Strober?
ScholarIQh-index
Bruce Strober has an h-index of 66 in OpenAlex.
What is the i10-index of Bruce Strober?
ScholarIQi10-index
Bruce Strober has an i10-index of 188 in OpenAlex.
What is the ORCID of Bruce Strober?
ScholarIQorcid
The ORCID for Bruce Strober is on the source record.
What is the OpenAlex record for Bruce Strober?
ScholarIQopenalex
The OpenAlex for Bruce Strober is on the source record.
What are the most-cited papers on Bruce Strober?
ScholarIQmost cited works
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Alan Menter, Bruce Strober, Daniel H. Kaplan, Darío Kivelevitch, Elizabeth Farley Prater, Benjamin K. Stoff, April W. Armstrong, Cody Connor, Kelly M. Cordoro, Dawn Marie R. Davis, Boni E. Elewski, Joel M. Gelfand, Kenneth B. Gordon, Alice B. Gottlieb, Arthur Kavanaugh, Matthew Kiselica, Neil J. Korman, Daniela Kroshinsky, Mark Lebwohl, Craig L. Leonardi, Jason Lichten, Henry W. Lim, Nehal N. Mehta, Amy S. Paller, Sylvia L. Parra, Arun L. Pathy, Reena Rupani, Michael Siegel, Emily Wong, Jashin J. Wu, Vidhya Hariharan, Craig A. Elmets
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Alan Menter, Stephen K. Tyring, Kenneth B. Gordon, Alexa B. Kimball, Craig L. Leonardi, Richard G. Langley, Bruce Strober, Martin Kaul, Yihua Gu, Martin M. Okun, Kim Papp
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
C.E.M. Griffiths, Bruce Strober, Peter van de Kerkhof, Vincent Ho, Roseanne Fidelus-Gort, Newman Yeilding, Cynthia Guzzo, Yichuan Xia, Bei Zhou, Shu Li, Lisa T. Dooley, Neil Goldstein, Alan Menter
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Mark Lebwohl, Bruce Strober, Alan Menter, Kenneth B. Gordon, Jolanta Węgłowska, L. Puig, Kim Papp, Lynda Spelman, Darryl Toth, Francisco A. Kerdel, April W. Armstrong, Georg Stingl, Alexa B. Kimball, H. Bachelez, Jashin J. Wu, Jeffrey Crowley, Richard G. Langley, Tomasz Blicharski, C. Paul, J.‐P. Lacour, Stephen K. Tyring, Leon Kircik, Sergio Chimenti, Kristina Callis Duffin, Jerry Bagel, John Koo, Gary Aras, Joanne Li, Wenjie Song, Cassandra E. Milmont, Yifei Shi, Ngozi Erondu, Paul Klekotka, Brian L. Kotzin, Ajay Nirula
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
Kenneth B. Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim Papp, Howard Sofen, L. Puig, Peter Foley, Mamitaro Ohtsuki, Mary Flack, Ziqian Geng, Yihua Gu, Joaquin Valdes, Elizabeth H. Thompson, H. Bachelez